Clinical trials in Dresden – page 14

965 clinical trials in Dresden, Germany across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Dresden at a glance

965

clinical trials

Research sites4

Quick filters

965 trials in Dresden

Open in trial search

Allogenic stem cell transplantation

Recruiting

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Ospedale Pediatrico Bambino Gesu

Contact Research Centre

Breast cancer+3

Recruiting

A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

Registered drugNo placebo

A Study Comparing GDC-4198 Alone and with Giredestrant versus Abemaciclib with Giredestrant for Advanced Breast Cancer After Previous CDK4/6 Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Genentech Inc.

Contact Research Centre

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Recruiting

Investigational

A study testing RO7790121 for moderate to severe rheumatoid arthritis in patients who did not respond to or cannot tolerate TNF or JAK inhibitor treatments

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Study of ribociclib with or without chemotherapy for patients with hormone receptor positive, HER2 negative early breast cancer at intermediate risk

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Unicancer

Contact Research Centre

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

Germany

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:AZD8205
Sponsor:AstraZeneca AB

Contact Research Centre

Clear cell renal cell carcinoma

Recruiting

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

A Study Testing Casdatifan and Cabozantinib Compared to Placebo and Cabozantinib in Patients With Advanced Clear Cell Kidney Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:AB521
Sponsor:Arcus Biosciences Inc.

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:AstraZeneca AB

Contact Research Centre

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug

Germany

Participants:18–64 years
Substances:Dapagliflozin
Sponsor:University Of Cologne

Contact Research Centre

Prostate cancer

Recruiting

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Amgen Inc.

Contact Research Centre

Renal cell carcinoma

Recruiting

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Dresden

What the registry says about research in the country

01 Respiratory Disease Research

Innovative clinical trials focusing on respiratory infections and preventive treatments, including studies of vaccines against RSV and human metapneumovirus in older adults.

Respiratory Syncytial Virus Prevention
Chronic Rhinosinusitis Treatment
Viral Respiratory Infections

Multiple studies evaluating both therapeutic and preventive approaches for respiratory conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including trials for breast cancer, gastric cancer, and pancreatic cancer treatments.

Advanced Cancer Therapeutics
Targeted Cancer Treatments
Immunotherapy Research

Focus on innovative treatment approaches and combination therapies for various cancer types.

03 Autoimmune Conditions

Studies examining treatments for various autoimmune disorders, including psoriatic arthritis and plaque psoriasis.

Inflammatory Disease Management
Novel Therapeutic Approaches
Chronic Disease Treatment

Investigation of new therapeutic options for patients with autoimmune and inflammatory conditions.

Back to Germany All countries